期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
PSMA4在肺腺癌预后、诊断和免疫浸润中的作用和机制研究 被引量:1
1
作者 赵静 李艳梅 +5 位作者 王雪樾 聂恬 王洁 翁启明 张静 范晔 《陆军军医大学学报》 CAS CSCD 北大核心 2024年第17期1985-1993,共9页
目的探究PSMA4在肺腺癌(lung adenocarcinoma,LUAD)预后、诊断和免疫浸润中的作用和机制。方法从癌症基因组图谱(the cancer genome atlas,TCGA)数据库中获取LUAD患者的表达谱和临床信息。通过Wilcoxon秩和检验比较LUAD组(n=539)与正常... 目的探究PSMA4在肺腺癌(lung adenocarcinoma,LUAD)预后、诊断和免疫浸润中的作用和机制。方法从癌症基因组图谱(the cancer genome atlas,TCGA)数据库中获取LUAD患者的表达谱和临床信息。通过Wilcoxon秩和检验比较LUAD组(n=539)与正常组(n=59)PSMA4基因的表达水平。通过在GEO数据库下载GSE40791和GSE10072 LUAD数据集,验证PSMA4在LUAD组与正常组中的表达水平。收集10对2023年1-12月在陆军军医大学第二附属医院呼吸科进行纤维支气管镜肺活检术的LUAD患者的肿瘤和癌旁组织样本。采用RT-qPCR技术验证PSMA4在10对LUAD和癌旁组织中的表达。体外培养肺癌细胞和正常肺上皮细胞,通过RT-qPCR检测PSMA4在各组细胞中的表达。并对PSMA4的高低表达组进行了功能富集分析和免疫细胞浸润分析,通过Cox回归分析和Kaplan-Meier(KM)法确定PSMA4对于LUAD的诊断和预后的价值,并构建列线图预测不同时间点的总生存率。结果TCGA数据集、GSE40791和GSE10072 LUAD数据集中的表达数据显示,PSMA4在LUAD组中的表达明显高于正常组(P<0.01)。RT-qPCR检测分析发现,PSMA4在LUAD和肺癌细胞中的表达显著高于癌旁组织和正常肺上皮细胞(P<0.01)。PSMA4高表达是诊断LUAD和预后不良的标志物,与肿瘤微环境中效应记忆性T细胞、滤泡辅助性T细胞、B淋巴细胞、自然杀伤细胞、中央记忆性T细胞、肥大细胞的水平的降低有关。结论PSMA4对LUAD有良好的诊断效能,并且与LUAD的预后和免疫浸润密切相关。 展开更多
关键词 肺腺癌 psma4 预后 诊断 免疫浸润
原文传递
Magnetic melamine cross-linked polystyrene-alt-malic anhydride copolymer:Synthesis,characterization,paclitaxel delivery,cytotoxic effects on human ovarian and breast cancer cells
2
作者 RAZIEH MOMEN-MESGIN JAFAR REZAIE +1 位作者 VAHID NEJATI PEYMAN NAJAFI MOGHADAM 《Oncology Research》 2025年第3期665-674,共10页
Objectives:Due to systematic side effects,there is a growing interest in nanoparticle formulation of anticancer drugs.Here,we aimed to synthesize poly(styrene-alt-maleic anhydride)cross-linked by melamine(PSMA/Me)and ... Objectives:Due to systematic side effects,there is a growing interest in nanoparticle formulation of anticancer drugs.Here,we aimed to synthesize poly(styrene-alt-maleic anhydride)cross-linked by melamine(PSMA/Me)and coated with magnetite nanoparticles(MNPs)PSMA/Me/Fe_(3)O_(4).In addition,we aimed to load paclitaxel(PTX)into PSMA/Me/Fe_(3)O_(4)for drug delivery and anticancer investigations.Methods:Novel PSMA/Me was synthesized via free radical copolymerization,coated with Fe_(3)O_(4),and then used as a transporter for PTX delivery.Fabricated copolymer was characterized using SEM,TGA,and XRD techniques.Drug release rate and loading efficiency were investigated.Human ovarian cancer cells(Skov-3)and breast cancer cells(MCF-7 cells)were incubated with the serial concentration of either free PTX or PSMA/Me/Fe_(3)O_(4)/PTX for cell viability and IC_(50)analysis for 24 and 48 h.Results:Characterization methods confirmed PSMA/Me copolymer formation.The results showed a significant encapsulation efficiency of 83%.The drug release analysis exhibited that PSMA/Me/Fe_(3)O_(4)/PTX may be considered pH-sensitive nanocarriers.PSMA/Me/Fe_(3)O_(4)/PTX reduced cell viability both dose and time-dependently(p<0.05).IC50 values of PSMA/Me/Fe_(3)O_(4)/PTX were low when compared to free PTX either 24 or 48 h post-treatment.Conclusions:Our results indicated that PSMA/Me/Fe_(3)O_(4)/PTX was more cytotoxic than PTX in both cancer cells.Findings indicated the potential of PSMA/Me/Fe_(3)O_(4)/PTX as an anticancer nanocarrier system. 展开更多
关键词 Breast cancer Ovarian cancer PSMA/Me Fe_(3)O_(4)MNPs Paclitaxel(PTX)
暂未订购
上一页 1 下一页 到第
使用帮助 返回顶部